CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

NCT03739554 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

5

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Chronic Lymphocytic Leukemia

Interventions

DRUG: CYC065
DRUG: Venetoclax

Sponsor

Cyclacel Pharmaceuticals, Inc.